Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
June 10, 2002
- Kaken: Sales Up 4.2%, Effects of Competitors on Artz Are Minimal
June 10, 2002
- Taisho Licenses mGluR Agonists to Merck
June 10, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 10, 2002
- SSP: Sales, Profits Plummet Due to Slump in Self-medication
June 10, 2002
- Chugai, Biostar, Jicchuken Create Post-genomic Research Company in Singapore
June 10, 2002
- Late PII Results on Humanized Antibody MRA Reported: Chugai
June 10, 2002
- Mochida: Sales Down Due to Decline in Mainstays
June 10, 2002
- Sosei Introduces Brain Tumor Treatment from KS Biomedix of the UK
June 10, 2002
- Fulminant Type 1 Diabetes Can Be Fatal if not Treated Immediately
June 10, 2002
- Kyorin: New Record-high Consolidated Sales Reported
June 10, 2002
- Santen Signs Agreement with Koken for Dry Eye Products
June 10, 2002
- MEDICAL DEVICE NEWS IN BRIEF
June 10, 2002
- We Are in Predawn of Radical Reform: Mr Nagayama of JPMA
June 3, 2002
- New Shionogi Cephem Antibiotic Shows Good Effects on MRSA
June 3, 2002
- Dainippon Licenses Ca Antagonist from Recordati
June 3, 2002
- Panasonic Develops High-throughput Drug Screening Technology
June 3, 2002
- Mitsubishi Chemical: Pharma Sales Up 81.3% to \231.1 Bil.
June 3, 2002
- OTC NEW IN BRIEF
June 3, 2002
- MPC: Radicut, Overseas Sales Boosts Sales, Profits
June 3, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…